NCT06196840Active, not recruitingPhase 2
Safety and Efficacy of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
A Phase 2, Randomized Controlled, Open-Label Study to Establish the Safety and Efficacy of LX102 in Patients With Neovascular Age-related Macular Degeneration (nAMD) (VENUS)
Source: ClinicalTrials.gov · Last updated 6 Mar 2026
Brief summary (registry, in English)
The goal of this study is to evaluate the overall safety and efficacy of LX102 gene therapy for nAMD.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 25 Dec 2023
- Start date
- 24 Jan 2024
- Primary completion date
- 24 Jun 2025
- Lead sponsor
- Innostellar Biotherapeutics Co.,Ltd
- Diseases
- Macular degeneration
- NCT number
- NCT06196840
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 50
- From 24 Jan 2024 to the primary completion date, 24 Jun 2025
- 11 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- CNV or macular edema in the study eye secondary to diseases other than nAMD.
- Retinal detachment, uveitis, uncontrolled glaucoma in the study eye, or any condition preventing visual acuity improvement.
- Acute coronary syndrome, myocardial infarction or coronary artery revascularization, CVA, TIA in the last 6 months.
- Uncontrolled hypertension defined as average SBP ≥160 mmHg or an average DBP ≥100 mmHg.
Lab values
- Uncontrolled diabetes defined as HbA1c \>8.0%.
Other
- Absence of RPE tear at Screening.
Who the study is looking for
- Willing to sign the informed consent, and willing to attend follow-up visits.
- Age ≥ 50, and ≤ 89.
- Diagnosis of active CNV secondary to neovascular AMD.
- BCVA ETDRS letters between 19 and 73.
- Demonstrated a meaningful response to anti-VEGF therapy.
Age in the registry: 50 years to 89 years · Sex: All · Does not accept healthy volunteers
Sites (11)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking Union Medical College Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
| West China Hospital of Sichuan University Coordinator of this site? Confirm its status | Chengdu | China | Unknown status |
| Zhongshan Ophthalmic Center of Sun Yat-Sen University Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| Guangzhou Aier Eye Hospital Coordinator of this site? Confirm its status | Guangzhou | China | Unknown status |
| Zhejiang University Eye Hospital Coordinator of this site? Confirm its status | Hangzhou | China | Unknown status |
| Anhui Provincial Hospital Coordinator of this site? Confirm its status | Hefei | China | Unknown status |
| Shanghai Eye and ENT Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| Shanghai General Hospital Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
| Shanxi Eye Hospital Coordinator of this site? Confirm its status | Taiyuan | China | Unknown status |
| Tianjin Medical University Eye Hospital Coordinator of this site? Confirm its status | Tianjin | China | Unknown status |
| Xuzhou No.1 People's Hospital Coordinator of this site? Confirm its status | Xuzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.